Generalized thymoma-associated myasthenia gravis associated with anti-α-amino-3-hydroxy-5-methyl-4 isoxazolepropionic acid receptor antibody encephalitis: A case report.

Authors

Jun Soma, Jun Sawada, Momoko Nanbu, Rei Ando, Shiori Kikuchi-Takeguchi, Keiko Tanaka, Naoki Nakagawa

Published in

Medicine. Volume 105. Issue 34. Pages e50330. Aug 21, 2026.

Abstract

Autoimmune neurological disorders, including myasthenia gravis and autoimmune encephalitis, may occur in association with thymoma, warranting careful neurological surveillance. Generalized thymoma-associated myasthenia gravis (g-TAMG) complicated with anti-α-amino-3-hydroxy-5-methyl-4 isoxazolepropionic acid receptor (AMPAR) antibody encephalitis is rare, and its clinical features remain unclear.
A 53-year-old Japanese man was followed up at our department for g-TAMG. The thymoma was classified as B1/B2 mixed according to the World Health Organization classification. He initially developed insomnia, followed by progressive tremors in both upper limbs, dysphagia, and gait disturbance. He subsequently began to experience repeated falls.
Brain magnetic resonance imaging upon admission revealed hyperintense lesions in the extensive cerebral cortex on fluid-attenuated inversion recovery and diffusion-weighted imaging. During this course, serum and cerebrospinal fluid tested positive for AMPAR antibodies, leading to a diagnosis of AMPAR antibody encephalitis.
Intravenous methylprednisolone pulse therapy, intravenous immunoglobulin therapy, and plasma exchange therapy were administered, followed by rituximab.
The neurological prognosis remained poor.
Immunotherapy with rituximab for generalized thymoma-associated myasthenia gravis (g-TAMG) associated with AMPAR antibody encephalitis showed no favorable outcomes. The poor prognosis may have been influenced by the fulminant encephalitis type and residual thymic tumor pathology. Although AMPAR antibody encephalitis is a rare complication of thymoma, its involvement should be considered when patients with thymoma develop central nervous system symptoms.

PMID:
42629701
Bibliographic data and abstract were imported from PubMed on 22 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.